Testing a new antibody treatment for kidney protein disease

Plain-English translation of NCT07157787 on ClinicalTrials.gov ↗ · Source last updated June 2026 · Translation generated October 2026 · How we translate trials

Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.

What is this trial?

This trial is testing whether , a new injectable medication, works better than a placebo in treating primary membranous nephropathy—a kidney disease where your kidneys leak too much protein into your urine. You would receive this medication along with standard kidney-protective treatments (blood pressure medicine and rituximab). The study will measure whether this treatment slows down or stops the progression of your kidney disease.

Primary membranous nephropathy is a serious kidney condition that can lead to kidney failure even when patients are already on standard treatments. This trial is looking for a new way to help patients at highest risk of getting worse by testing whether this medication can offer additional protection beyond current options.

Do you qualify?

You likely qualify if…

you have been diagnosed with primary membranous nephropathy confirmed by a positive antibody test (anti-PLA2R)
you have been on ACE inhibitor or ARB blood pressure medication for at least 8 weeks at the highest dose you can tolerate
you have protein in your urine measuring more than 3.5 grams per day on at least two separate tests, with the second test showing little improvement
your kidney function is relatively preserved with an eGFR of 60 mL/min/1.73 m² or higher
you are willing to receive rituximab and take antibiotics and a meningitis vaccine as part of the standard care

You likely don't qualify if…

you have experienced a sudden, serious worsening of your kidney function recently
you have had a life-threatening kidney condition called nephrotic syndrome within the past year
you have already received a kidney transplant, are planning one, or currently need dialysis
you have a history of severe allergic reactions to ACE inhibitors or ARB blood pressure medications
you are currently taking other kidney-protective medications like MRA, ERA, or SGLT2 inhibitors that you haven't been on for at least 12 weeks

What participation looks like

You will be randomly assigned to receive either the new medication or a placebo—both given as an injection under the skin. All participants also receive standard kidney-protective treatments including ACE inhibitor or ARB blood pressure medicine and rituximab. The study will track your kidney function and urine protein levels over time to see if the new medication helps slow disease progression. You'll have regular clinic visits and blood and urine tests to monitor your response and safety.

AI-generated summary from trial data · Oct 12, 2026 · Not medical advice

Trial locations(40 sites)

United States

Research Site, Loma Linda, California

Research Site, San Diego, California

Research Site, Minneapolis, Minnesota

Research Site, Rochester, Minnesota

Research Site, Houston, Texas